Akari Therapeutics announces 1-for-40 reverse ADS ratio change to meet Nasdaq bid price requirement

Akari Therapeutics Plc

ADS ratio changes from 1:2,000 to 1:80,000 ordinary shares; each 40 current ADSs become 1 new ADS effective March 31, 2026.
No change to underlying ordinary shares; fractional ADSs will be aggregated and sold with cash proceeds distributed.
Action intended to maintain compliance with Nasdaq minimum bid price requirement for continued listing.
Trading continues on Nasdaq under symbol AKTX; Deutsche Bank will handle the exchange.

item 3.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Akari Therapeutics Plc issued common stock.

Security: common stock

Exact text from the filing

On March 17, 2026, Akari Therapeutics, Plc (the “Company”) announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) evidencing ordinary shares, par value 0.000000005 per share (“Ordinary Shares”), from one (1) ADS representing two thousand (2,000) Ordinary Share to one (1) ADS representing eighty thousand (80,000) Ordinary Shares (the “Ratio Change”).

View on SEC.gov

Browse all equity issuances →

Akari Therapeutics Plc filing history →

Source: SEC EDGAR

accession 0001493152-26-010602

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.